ScoreWhy is Glenmark Pharmaceuticals Ltd. ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.13 times
2
The company has declared Positive results for the last 3 consecutive quarters
- PAT(Latest six months) At Rs 1,133.97 cr has Grown at 103.40%
- ROCE(HY) Highest at 40.16%
- NET SALES(9M) Higher at Rs 13,718.08 cr
3
With ROE of 26.9, it has a Attractive valuation with a 5.8 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 29.01%, its profits have risen by 125.6% ; the PEG ratio of the company is 0.2
4
High Institutional Holdings at 39.67%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Glenmark Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Glenmark Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Glenmark Pharma
29.01%
0.94
30.92%
Sensex
-5.98%
-0.45
13.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.19%
EBIT Growth (5y)
19.50%
EBIT to Interest (avg)
7.97
Debt to EBITDA (avg)
1.37
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
1.12
Tax Ratio
31.38%
Dividend Payout Ratio
6.74%
Pledged Shares
0
Institutional Holding
39.67%
ROCE (avg)
19.22%
ROE (avg)
12.43%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
22
Industry P/E
34
Price to Book Value
5.79
EV to EBIT
15.07
EV to EBITDA
13.18
EV to Capital Employed
6.07
EV to Sales
3.55
PEG Ratio
0.17
Dividend Yield
0.23%
ROCE (Latest)
40.27%
ROE (Latest)
26.86%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
PAT(Latest six months)
At Rs 1,133.97 cr has Grown at 103.40%
ROCE(HY)
Highest at 40.16%
NET SALES(9M)
Higher at Rs 13,718.08 cr
DEBT-EQUITY RATIO(HY)
Lowest at 0.06 times
-5What is not working for the Company
PBT LESS OI(Q)
At Rs 572.09 cr has Fallen at -36.2% (vs previous 4Q average
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.37 times
NET SALES(Q)
At Rs 3,770.59 cr has Fallen at -8.4% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for Glenmark Pharma
Profit After Tax (PAT) - Latest six months
At Rs 1,133.97 cr has Grown at 103.40%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.06 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Glenmark Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 572.09 cr has Fallen at -36.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 896.81 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Net Sales - Quarterly
At Rs 3,770.59 cr has Fallen at -8.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 4,117.03 CrMOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Debtors Turnover Ratio- Half Yearly
Lowest at 3.37 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
